Zymeworks BC Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-12-10: Form 8-K; Period of report 2020-12-10; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2020-12-04: Form 8-K; Period of report 2020-12-04; Description 8.01 Other Events; Details 8.01.
- 2020-12-02: Form 8-K; Period of report 2020-12-02; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2020-12-01: Form 8-K; Period of report 2020-12-01; Description 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-12-10 | 8-K | 2020-12-10 | 7.01 Regulation FD Disclosure | 7.01 On December 10, 2020, Zymeworks Inc. (“Zymeworks”) issued a press release announcing the selection of three abstracts for presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually on January 15 – 17, 2021. | d75372d8k.htm |
| 2020-12-04 | 8-K | 2020-12-04 | 8.01 Other Events | 8.01 Zymeworks Inc. (the “Company”) is filing this Current Report on Form 8-K to provide a copy of the legal opinion of Blake, Cassels & Graydon LLP relating to the legality of the Company’s common shares, no par value per share, to be offered and sold pursuant the Company’s Registration Statement on Form S-3ASR (No. 333-234517) and the related prospectus supplement, dated December 4, 2020, and filed with the U.S. Securities and Exchange Commission pursuant to Rule 424 under the Securities Act. | d70283d8k.htm |
| 2020-12-02 | 8-K | 2020-12-02 | 7.01 Regulation FD Disclosure | 7.01 On December 2, 2020, Exelixis, Inc. (“Exelixis”), Iconic Therapeutics, Inc. (“Iconic”) and Zymeworks Inc. (“Zymeworks”) issued a joint press release announcing that Exelixis has exercised its exclusive option for Iconic’s lead oncology antibody-drug conjugate (ADC) program under a May 2019 agreement between Exelixis and Iconic. | d92041d8k.htm |
| 2020-12-01 | 8-K | 2020-12-01 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On December 1, 2020, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that its partner, BeiGene, Ltd. (“BeiGene”), has dosed the first patient in South Korea in a pivotal, single-arm clinical trial of zanidatamab (formerly ZW25) monotherapy in patients with advanced or metastatic HER2-amplified biliary tract cancer. 8.01 On December 1, 2020, Zymeworks also filed a material change report with Canadian securities regulators regarding BeiGene having dosed the first patient in South Korea in a pivotal, single-arm clinical trial of zanidatamab (formerly ZW25) monotherapy in patients with advanced or metastatic HER2-amplified biliary tract cancer and that Zymeworks will receive a US$10 million payment under its collaboration with BeiGene as a result of the achievement of this development milestone. | d65018d8k.htm |
| 2020-11-30 | 8-K | 2020-11-30 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On November 30, 2020, Zymeworks Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for zanidatamab in patients with previously-treated HER2 gene-amplified biliary tract cancer. 8.01 On November 30, 2020, the Company also filed a material change report with Canadian securities regulators regarding the U.S. Food and Drug Administration’s grant of Breakthrough Therapy designation for zanidatamab in patients with previously-treated HER2 gene-amplified biliary tract cancer. | d40412d8k.htm |
| 2020-11-19 | 8-K | 2020-11-19 | 7.01 Regulation FD Disclosure | 7.01 On November 19, 2020, Zymeworks Inc. issued a press release announcing that the European Commission (EC) has granted Orphan Drug designation for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in patients with gastric cancer. | d81105d8k.htm |
| 2020-11-16 | 8-K | 2020-11-16 | 7.01 Regulation FD Disclosure | 7.01 On November 16, 2020, Zymeworks Inc. (the “Zymeworks”) issued a press release announcing that Zymeworks and ALX Oncology Holdings Inc. have entered into a clinical collaboration to evaluate the combination of Zymeworks’ zanidatamab (formerly ZW25), a HER2-targeted bispecific antibody, and ALX148, a CD47 blocker, for the treatment of patients with advanced HER2-expressing breast cancer and other solid tumors. | d94017d8k.htm |
| 2020-11-10 | 8-K | 2020-11-10 | 7.01 Regulation FD Disclosure | 7.01 • Stifel’s 2020 Virtual Healthcare Conference is scheduled for November 16-18, 2020. | d938912d8k.htm |
| 2020-11-03 | 8-K | 2020-11-03 | 2.02 Results of Operations and Financial Condition | 2.02 On November 3, 2020, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2020. | zyme-20201103.htm |
| 2020-09-03 | 8-K/A | 2020-08-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 (d) On August 31, 2020, the Board formed the R&D Committee, consisting of Natalie Sacks (Chair), Kenneth Hillan and Dr. Neu. 7.01 On September 3, 2020, Zymeworks issued a press release announcing that management will participate in three upcoming virtual investor conferences. | d52397d8ka.htm |
| 2020-08-05 | 8-K | 2020-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2020, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2020. | zyme-20200805.htm |
| 2020-07-09 | 8-K | 2020-07-08 | 7.01 Regulation FD Disclosure | 7.01 On July 8, 2020, Zymeworks Inc. (the “Company”) issued a press release summarizing matters discussed on a webcast and conference call hosted by the Company highlighting its progress and key accomplishments in the first half of 2020. | d945550d8k.htm |
| 2020-07-08 | 8-K | 2020-07-08 | 7.01 Regulation FD Disclosure | 7.01 On July 8, 2020, Zymeworks Inc. (the “Company”) issued a press release announcing that the Company and its long-time partner, Merck (known as MSD outside the US and Canada), have signed a new license agreement granting Merck the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric™ and EFECT™ platforms. | d945372d8k.htm |
| 2020-06-30 | 8-K | 2020-06-30 | 7.01 Regulation FD Disclosure | 7.01 On June 30, 2020, Zymeworks Inc. (the “Company”) issued a press release announcing that the Company will host a webcast and conference call on Wednesday, July 8, 2020 at 4:30pm ET (1:30pm PT) to discuss progress on its corporate priorities and upcoming catalysts. | d941825d8k.htm |
| 2020-05-28 | 8-K | 2020-05-28 | 7.01 Regulation FD Disclosure | 7.01 On May 28, 2020, Zymeworks Inc. (the “Company”) issued a press release announcing that Zymeworks will present at the upcoming Jefferies 2020 Virtual Healthcare Conference taking place June 2-4, 2020. | d935577d8k.htm |
| 2020-05-08 | 8-K | 2020-05-07 | 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure | 5.07 On May 7, 2020, Zymeworks Inc. (the “Company”), held its 2020 annual meeting of shareholders (the “Annual Meeting”). 7.01 On May 8, 2020, the Company issued a press release announcing the voting results of its Annual Meeting, which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. | d926828d8k.htm |
| 2020-05-07 | 8-K | 2020-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2020, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2020. | zyme-20200507.htm |
| 2020-04-01 | 8-K | 2020-04-01 | 7.01 Regulation FD Disclosure | 7.01 On April 1, 2020, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that its partner, BeiGene, Ltd. (“BeiGene”), has dosed the first patient in a two-arm Phase 1b/2 trial evaluating Zymeworks’ HER2-targeted bispecific antibody ZW25 in combination with chemotherapy as a first-line treatment for patients with metastatic HER2-positive breast cancer and in combination with chemotherapy and BeiGene’s PD-1-targeted antibody tislelizumab as a first-line treatment for patients with metastatic HER2-positive gastroesophageal adenocarcinoma (GEA). | d905486d8k.htm |
| 2020-03-16 | 8-K | 2020-03-16 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 On March 16, 2020, Zymeworks Inc. (the “Company”) entered into a registration rights agreement (the “Agreement”) with Baker Brothers Life Sciences, L.P. and 667, L.P. (collectively, the “Baker Funds”), pursuant to which the Baker Funds are entitled to certain resale registration rights with respect to common shares of the Company held by the Baker Funds (“Registrable Securities”). 5.02 (d) On March 16, 2020, Dr. Kelvin Neu was appointed to the board of directors (the “Board”) of the Company. 7.01 On March 16, 2020, the Company issued a press release announcing Dr. Neu’s appointment to the Board. 8.01 On March 16, 2020, the Company also filed a material change report with Canadian securities regulators regarding Dr. Neu’s appointment to the Board. | d900170d8k.htm |
| 2020-03-02 | 8-K | 2020-03-02 | 2.02 Results of Operations and Financial Condition | 2.02 On March 2, 2020, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2019. | d891210d8k.htm |
| 2020-02-24 | 8-K | 2020-02-24 | 7.01 Regulation FD Disclosure | 7.01 On February 24, 2020, Zymeworks Inc. (the “Company”) issued a press release announcing that the Company will present at the upcoming Raymond James Institutional Investors Conference taking place March 1-4, 2020 in Orlando, FL. | d893418d8k.htm |
| 2020-01-27 | 8-K | 2020-01-27 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On January 21, 2020, Zymeworks issued a press release announcing the filing of a preliminary prospectus supplement in connection with the issuance and sale of 4,924,729 of the Company’s common shares and in lieu of common shares, to a certain investor, pre-funded warrants to purchase up to 1,075,271 common shares (the “Offering”), which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com (the “Launch Press Release”). 8.01 On January 27, 2020, Zymeworks filed a material change report regarding the launch, pricing and closing of the Offering, as described in the Launch Press Release, the Pricing Press Release and the Closing Press Release with the Canadian securities regulatory authorities. | d878707d8k.htm |
| 2020-01-24 | 8-K | 2020-01-21 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 On January 22, 2020, Zymeworks Inc. (“Zymeworks” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Citigroup Global Markets Canada Inc. as representatives of the several underwriters named in Schedule II thereto (the “Underwriters”), relating to the issuance and sale of 4,924,729 of the Company’s common shares and, in lieu of common shares, to a certain investor, pre-funded warrants to purchase up to 1,075,271 common shares (together the “Offered Securities”). 7.01 On January 21, 2020, Zymeworks issued a press release announcing the filing of a preliminary prospectus supplement in connection with the Offering, which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. | d868443d8k.htm |
| 2020-01-13 | 8-K | 2020-01-12 | 7.01 Regulation FD Disclosure | 7.01 On January 12, 2020, Zymeworks Inc. issued a press release announcing the initiation of a Phase 2 trial evaluating ZW25 combination therapy and an agreement with Pfizer which advances the study. | d861788d8k.htm |
| 2020-01-07 | 8-K | 2020-01-07 | 8.01 Other Events | 8.01 On January 7, 2020, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that management will present a corporate overview and updated clinical development plans for its lead candidates ZW25 and ZW49 at the upcoming 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 3:30 p.m. | d863821d8k.htm |